4-(2,3-二羟基丙氧基)-4-氧代丁酸 | 94199-49-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 4-(2,3-二羟基丙氧基)-4-氧代丁酸
• 中文别名: 2-氨基-N-[(1-乙基哌啶-2-基)甲基]-4-甲氧基嘧啶-5-甲酰胺
• 英文名称: glycerol succinate
• 英文别名: succinic acid 2,3-dihydroxy-propyl ester；(2,3-Dihydroxypropyl) hydrogen succinate；4-(2,3-dihydroxypropoxy)-4-oxobutanoic acid
• CAS: 94199-49-2
• 化学式: C₇H₁₂O₆
• 分子量: 192.169
• InChiKey: DQHHKFVACXSZHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Non-nucleoside reverse transcriptase inhibitors
  申请人：——

  公开号：US20020128301A1

  公开（公告）日：2002-09-12

  Non-nucleoside reverse transcriptase inhibitors of formula (P-1) wherein: Ar1 is an unsaturated, optionally substituted, mono or bicyclic ring structure comprising 0 to 3 hetero atoms selected from S, O and N; Ar2 is an aromatic, optionally substituted, monocyclic ring structure comprising at least one nitrogen hetero atom and zero to two further hetero atoms selected from S, O and N; R4 and R5 are independently H or C 3 -C 8 cycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 5 alkoxy, C 1 -C 4 alkanoyloxy, C 1 -C 4 alkylthio, amino, carboxy, carbamoyl, cyano, halo, hydroxy, aminomethyl, hydroxymethyl, carboxymethyl, or halo substituted C 1 -C 6 alkyl mercapto, nitro; or R4 and RS join to form a 3-6 membered, optionally substituted ring structure; R6 is 0 or S; Rx is the residue of a natural or unnatural amino acid; and L* is a linker moiety which is ether-, carbonate- or ester-bound to the adjacent oxygen and ester linked to Rx; and pharmaceutically acceptable salts thereof are anti-HIV agents with favourable pharmacokinetic properties.

  非核苷类逆转录酶抑制剂的化学式（P-1），其中：Ar1是一种不饱和的、可选择取代的、单环或双环结构，包括0至3个来自S、O和N的杂原子；Ar2是一种芳香的、可选择取代的、单环结构，包括至少一个氮杂原子和0至2个来自S、O和N的进一步杂原子；R4和R5独立地是H或C3-C8环烷基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C5烷氧基、C1-C4烷酰氧基、C1-C4烷基硫氧基、氨基、羧基、氨基甲酰基、氢氰基、卤素基、羟基、氨甲基、羟甲基、羧甲基或卤素取代的C1-C6烷基巯基、硝基；或者R4和RS结合形成一个3-6成员的、可选择取代的环结构；R6是0或S；Rx是天然或非天然氨基酸的残基；L*是与相邻氧原子以醚键、碳酸酯键或酯键相连的连接基团，与Rx酯键相连；以及其药学上可接受的盐是具有良好药代动力学性质的抗HIV药物。
• [EN] COMBINATION THERAPY<br/>[FR] TRAITEMENT COMBINÉ
  申请人：CARNOT LLC

  公开号：WO2017147220A1

  公开（公告）日：2017-08-31

  The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.

  本公开提供了一些特定的联合治疗技术，特别适用于治疗可能与异常代谢相关的一种或多种疾病、疾病或症状。在某些实施例中，提供的技术提供了TCA循环酸和酮体的组合。在某些实施例中，提供的技术提供了TCA循环酸和其他羧酸的组合。
• PEG LIPIDS AND USES THEREOF
  申请人：Moderna TX, Inc.

  公开号：US20220047518A1

  公开（公告）日：2022-02-17

  The present disclosure in part provides compounds (i.e., PEG lipids) which are useful in pharmaceutical compositions, cosmetic compositions, and drug delivery systems, e.g, for use in lipid nanoparticle (LNP) formulations. The present disclosure also provides LNP formulations comprising PEG lipids described herein, and methods of using the same. For example, the LNPs provided herein are useful for the delivery of an agent (e.g, therapeutic agent) to a subject. The PEG lipids and LNPs provided herein, in certain embodiments, exhibit increased PEG shedding compared to existing PEG lipids and LNP formulations.

  本公开部分提供了化合物（即PEG脂质），这些化合物在制药组合物、化妆品组合物和药物递送系统中非常有用，例如用于脂质纳米粒（LNP）配方。本公开还提供了包含此处所述PEG脂质的LNP配方以及使用它们的方法。例如，此处提供的LNP对于将药物（例如治疗药物）递送到主体中非常有用。在某些实施例中，此处提供的PEG脂质和LNP表现出比现有的PEG脂质和LNP配方更高的PEG脱落。
• Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetic or detergents
  申请人：——

  公开号：US20040197460A1

  公开（公告）日：2004-10-07

  Disclosed are a fatty acid esters composition of a polyglycerine containing more than 70% of a fatty acid monoester which is defined by a specified analysis method, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, and a highly-purified fatty acid esters composition of a polyglycerine having an oxirane oxygen concentration of below 100 ppm which is defined by a specified analysis method. The fatty acid esters compositions of a polyglycerine are useful as additives for a variety of food-stuffs, additives for a variety of thermoplastic resins, and as additives for a variety of cosmetics or detergents.

  本发明涉及一种脂肪酸酯组合物，其中包含超过70％的脂肪酸单酯，该脂肪酸单酯由指定的分析方法定义，以及其制备方法，制备高度纯化的聚甘油脂肪酸酯组合物的方法，以及具有低于100 ppm的环氧氧含量的聚甘油脂肪酸酯组合物，该组合物由指定的分析方法定义。聚甘油脂肪酸酯组合物可用作各种食品添加剂、各种热塑性树脂的添加剂，以及各种化妆品或清洁剂的添加剂。
• 2-Iminopyrrolidine derivatives
  申请人：Suzuki Shuichi

  公开号：US20050245592A1

  公开（公告）日：2005-11-03

  A 2-iminopyrrolidine derivative represented by the formula: wherein ring B represents a benzene ring, pyridine ring, etc.; R 101 -R 103 represent hydrogen, halogen, C 1-6 alkyl, etc.; R 5 represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, etc.; R 6 represents hydrogen, C 1-6 alkyl, C 1-6 alkyloxycarbonyl, etc.; Y 1 represents a single bond, —CH 2 —, etc.; Y 2 represents a single bond, —CO—, etc.; and Ar represents hydrogen, a group represented by the formula: [wherein R 10 -R 14 represent hydrogen, C 1-6 alkyl, hydroxyl, C 1-6 alkoxy, etc.; and R 11 and R 12 or R 12 and R 13 may bond together to form a 5- to 8-membered heterocyclic ring], etc.}, or a salt thereof.

  一种2-伊米诺吡咯烷衍生物，其化学式为：其中环B代表苯环、吡啶环等；R101-R103代表氢、卤素、C1-6烷基等；R5代表氢、C1-6烷基、C1-6烷氧基-C1-6烷基等；R6代表氢、C1-6烷基、C1-6烷氧羰基等；Y1代表单键，-CH2-等；Y2代表单键，-CO-等；Ar代表氢，一个由以下式子表示的基团：[其中R10-R14代表氢、C1-6烷基、羟基、C1-6烷氧基等；R11和R12或R12和R13可以结合形成5-至8-成员的杂环]，等，或其盐。